| Chairman |
|
Frank Wu |
| Business Nature |
| 醫療保健 (Health Care) |
| Board Members |
Chairman & Chief Executive Officer: Frank Wu
Executive Director: Wu Di
Non-executive Director: Jia Zhongxin, Yi Hua
Independent Non-executive Director: Chui Hoi Yam, Zheng Zhelan, Li Shu Pai.
|
| Principle Business |
|
The Group is principally engaged in the research and development of pharmaceutical products. |
| Related Indexes | | Hang Seng Composite Index | Hang Seng Healthcare Index | | Hang Seng Composite SmallCap Index | Hang Seng Healthcare Industry Index |
|
| Major Shareholders |
| Frank Wu | 80,597,797 | H Sh | 20.20% | 26.53% | 2026/01/20 | | Frank Wu | 50,259,832 | NON-H SHS | 12.60% | 52.78% | 2026/01/20 | | Genecare Development Limited | 27,610,879 | H Sh | 6.96% | 9.15% | 2025/06/23 | | Future Industry Investment Fund II (Limited Partnership) | 24,274,756 | H Sh | - | 7.99% | 2026/01/20 | | PharmaBlock Sciences (Nanjing), Inc. | 22,107,247 | H Sh | 5.57% | 7.33% | 2025/06/23 | | SDIC Venture Capital Co., Ltd | 21,680,081 | H Sh | 5.46% | 7.19% | 2025/06/23 | | CPE Management International II Limited | 21,521,091 | NON-H SHS | 5.42% | 22.60% | 2025/06/23 | | GP Healthcare Capital Co., Ltd. | 17,153,860 | H Sh | 4.32% | 5.69% | 2025/06/23 |
|
|
|
|
|